- Home
- RETO vs ADAP Comparison
RETO vs ADAP Comparison
Compare RETO & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RETO
- ADAP
- Stock Information
- Founded
- RETO 1999
- ADAP 2008
- Country
- RETO China
- ADAP United Kingdom
- Employees
- RETO N/A
- ADAP N/A
- Industry
- RETO Multi-Sector Companies
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- RETO Consumer Discretionary
- ADAP Health Care
- Exchange
- RETO Nasdaq
- ADAP Nasdaq
- Market Cap
- RETO 24.7M
- ADAP 21.3M
- IPO Year
- RETO 2017
- ADAP 2015
- Fundamental
- Price
- RETO $1.71
- ADAP $0.05
- Analyst Decision
- RETO
- ADAP Hold
- Analyst Count
- RETO 0
- ADAP 6
- Target Price
- RETO N/A
- ADAP $1.02
- AVG Volume (30 Days)
- RETO 15.4K
- ADAP 82.1M
- Earning Date
- RETO 10-27-2025
- ADAP 08-13-2025
- Dividend Yield
- RETO N/A
- ADAP N/A
- EPS Growth
- RETO N/A
- ADAP N/A
- EPS
- RETO N/A
- ADAP N/A
- Revenue
- RETO $1,828,976.00
- ADAP $65,084,999.00
- Revenue This Year
- RETO N/A
- ADAP N/A
- Revenue Next Year
- RETO N/A
- ADAP $52.35
- P/E Ratio
- RETO N/A
- ADAP N/A
- Revenue Growth
- RETO N/A
- ADAP N/A
- 52 Week Low
- RETO $1.53
- ADAP $0.05
- 52 Week High
- RETO $17.20
- ADAP $1.32
- Technical
- Relative Strength Index (RSI)
- RETO 26.74
- ADAP 33.73
- Support Level
- RETO $1.82
- ADAP $0.06
- Resistance Level
- RETO $1.98
- ADAP $0.07
- Average True Range (ATR)
- RETO 0.13
- ADAP 0.01
- MACD
- RETO -0.00
- ADAP 0.01
- Stochastic Oscillator
- RETO 19.36
- ADAP 20.83
About RETO ReTo Eco-Solutions Inc.
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly-ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation and construction of urban ecological environments for capturing, controlling and re-using rainwater. It operates through four segments namely Machinery and Equipment sales, Construction materials sales, Municipal Construction Projects, and Technology Consulting and other services. The company earns its revenue from Machinery and Equipment sales segment. Geographically, it derives a majority of its revenue from China.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.